Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Maxim Group Downgrades Kintara Therapeutics to Hold

Maxim Group Downgrades Kintara Therapeutics to Hold

Maxim Group analyst Jason McCarthy downgrades Kintara Therapeutics (NASDAQ:KTRA) from Buy to Hold.

September 29, 2022

1 minute read

Maxim Group analyst Jason McCarthy downgrades Kintara Therapeutics (NASDAQ:KTRA) from Buy to Hold.

Where American Airlines Group Stands With Analysts

May 8, 1:00 PM

Analysts have provided the following ratings for American Airlines Group (NASDAQ:AAL) within the last quarter: Bullish Somewhat Bullish…

March 2, 7:28 AM

Canaccord Genuity analyst Joseph Vafi downgrades Silvergate Capital (NYSE:SI) from Buy to Hold and lowers the price target from $25 to $9.

November 30, 3:53 PM

Rosenblatt Securities believes Bakkt Holdings Inc’s (NYSE:BKKT) unique position in the cryptocurrency space has created a buying opportunity.

May 13, 5:00 PM

Lululemon Athletica (NASDAQ:LULU) has outperformed the market over the past 10 years by 12.06% on an annualized basis…